|Table of Contents|

The expression of PIM1 in diffuse large B-cell lymphoma tissue with co-expression of C-MYC/BCL2 and its relationship with clinicopathological characteristics

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

2023 13
Research Field:
Publishing date:


The expression of PIM1 in diffuse large B-cell lymphoma tissue with co-expression of C-MYC/BCL2 and its relationship with clinicopathological characteristics
XU RuihuanXU JuanYANG Wenxiu
Department of Pathology,the Affiliated Hospital of Guizhou Medical University,Guizhou Guiyang 550001,China.
double-expression lymphoma (DEL)diffuse large B-cell lymphomaHans classificationPIM1p65prognosis
Objective:To detect the mutation and expression of PIM1 gene in C-MYC/BCL2 double-expression diffuse large B-cell lymphoma (DEL),and to explore the relationship between PIM1 expression and clinical pathological features of DEL.Methods:Clinical cases diagnosed as DLBCL by the Department of Pathology of our hospital from January 1,2010 to December 31,2018 were collected.Immunohistochemistry (IHC) staining was used to detect the expression of C-MYC and BCL2 proteins.Qualified cases were selected for detecting the expression of p65.sanger sequencing were used to detect PIM1 mutations,and RT-qPCR was used to measure the expression of PIM1 mRNA.Cases were followed up and appropriate statistical methods were used for statistical analysis.Results:PIM1 gene mutation in DEL cases and its effect on PIM1 expression:39 DEL cases were included,the total mutation rate of PIM1 in DEL was 56.41% (22/39).The expression of PIM1 mRNA in the cases with/without PIM1 mutation was statistically different (P=0.012),and it was significantly increased in the PIM1 mutation group.NF-κB (p65) protein expression:The total positive expression rate was 53.85% (21/39),and respectively in non-GCB type DEL (16/23) was significantly higher than that in GCB type DEL (5/16) (P=0.025).The relationship between PIM1 expression and clinicopathological characteristics of DEL:The expression of PIM1 mRNA was also related to Ann Arbor staging and serum LDH level.It is significantly increased in late clinical stage or DEL cases with abnormally elevated serum LDH (P=0.046,P=0.048).The effect of PIM1,p65 on the expression of C-MYC and BCL2 in DEL:The expression of C-MYC protein in the p65 positive was statistically significantly increased compared with negative expression group(P=0.021).In DEL cases,the expression of C-MYC and BCL2 has relationship with PIM1 mRNA,PIM1 mRNA significantly increased with high expression(P=0.015,0.039).Conclusion:In DEL,there are high-frequency mutations in the PIM1 gene and up-regulation of RNA expression,the up-regulation of RNA expression of PIM1 mRNA may be related to its mutation,and abnormal PIM1 may be related to the poor prognostic characteristics of DEL.p65 influence C-MYC protein expression in DEL,not related to abnormal PIM1.


[1]CROMBIE JL,ARMAND P.Diffuse large B-cell lymphoma and high-grade B-cell lymphoma:Genetic classification and its implications for prognosis and treatment[J].Surg Oncol Clin N Am,2020,29(1):115-125.
[2]WANG KL,CHEN C,SHI PF,et al.Prognostic value of morphology and Hans classification in diffuse large B cell lymphoma[J].Journal of Experimental Hematology,2018,26(4):1079-1085.
[3]中国临床肿瘤学会指南工作委员会.中国临床肿瘤学会(CSCO)淋巴瘤诊疗指南2021[M].北京:人民卫生出版社,2021:36-37. Chinese Society of Clinical Oncology Guidelines Working Committee.Guidelines of Chinese society of clinical oncology(CSCO) lymphoid malignancies 2021[M].Beijing:People's Health Publishing House,2021:36-37.
[4]MA Z,NIU J,CAO Y,et al.Clinical significance of 'double-hit' and 'double-expression' lymphomas[J].J Clin Pathol,2020,73(3):126-138.
[5]DONATI G,AMATI B.MYC and therapy resistance in cancer:risks and opportunities[J].Mol Oncol,2022,16(21):3828-3854.
[6]LEE B,LEE H,CHO J,et al.Mutational profile and clonal evolution of relapsed/refractory diffuse large B-cell lymphoma[J].Front Oncol,2021,11:628807.
[7]SZYDOWSKI M,DEBEK S,PROCHOREC-SOBIESZEK M,et al.PIM kinases promote survival and immune escape in primary mediastinal large B-cell lymphoma through modulation of JAK-STAT and NF-κB activity[J].Am J Pathol,2021,191(3):567-574.
[8]WILLENBACHER E,WILLENBACHER W,WEGER R,et al.Patients with double/triple copy number gains on C-MYC,BCL2,and/or BCL6 treated with standard chemotherapy have a similarly poor prognosis than those with high-grade B cell lymphoma with C-MYC and BCL2 and/or BCL6 rearrangements:a single-center experience on a consecutive cohort of large B cell lymphomas[J].Ann Hematol,2020,99(9):2125-2132.
[9]SALAM D,THIT EE,TEOH SH,et al.C-MYC,BCL2 and BCL6 translocation in B-cell non-Hodgkin lymphoma cases [J].J Cancer,2020,11(1):190-198.
[10]冯江龙,杨文秀,王佳蕊,等.A20基因缺失对弥漫大B细胞淋巴瘤临床病理特征和预后的影响及相关分子机制研究[J].重庆医学,2017,46(19):2594-2598. FENG JL,YANG WX,WANG JR,et al.Impacts of A20 gene deletion on clinicopathological features and prognosis of diffuse large B cell lymphoma and relative molecular mechanism[J].Chongqing Medical,2017,46(19):2594-2598.
[11]XIE J,SHEN X,SHI Q,et al.Clinical significance of MYD88 non-L265P mutations in diffuse large B-cell lymphoma[J].Hematol Oncol,2022,40(5):885-893.
[12]HARRINGTON F,GREENSLADE M,TALAULIKAR D,et al.Genomic characterisation of diffuse large B-cell lymphoma[J].Pathology,2021,53(3):367-376.
[13]XU-MONETTE ZY,WEI L,FANG X,et al.Genetic subtyping and phenotypic characterization of the immune microenvironment and MYC/BCL2 double expression reveal heterogeneity in diffuse large B-cell lymphoma[J].Clin Cancer Res,2022,28(5):972-983.
[14]KNSTNER A,WITTE HM,RIEDL J,et al.Mutational landscape of high-grade B-cell lymphoma with MYC-,BCL2 and/or BCL6 rearrangements characterized by whole-exome sequencing[J].Haematologica,2022,107(8):1850-1863.
[15]XU J,LIU JL,MEDEIROS LJ,et al.MYC rearrangement and MYC/BCL2 double expression but not cell-of-origin predict prognosis in R-CHOP treated diffuse large B-cell lymphoma[J].Eur J Haematol,2020,104(4):336-343.
[16]韩莹,杨文秀,濮珍红,等.MicroRNA-125a-5p表达对弥漫大B细胞淋巴瘤耐药及临床预后的影响[J].中国现代医学杂志,2018,28(19):34-40. HAN Y,YANG WX,PU ZH,et al.Effect of miR-125a-5p expression on drug resistance and clinical prognosis of diffuse large B cell lymphoma[J].Chinese Journal of Modern Medicine,2018,28(19):34-40.
[17]庹樱篮,陈琴,杨文秀.A20突变与弥漫大B细胞淋巴瘤临床病理特征及预后的关系[J].中国肿瘤临床,2015,42(20):1018-1024. TUO YL,CHEN Q,YANG WX.Relationship of A20 mutation with clinicopathologic features and prognosis of diffuse large B cell lymphoma[J].China Clinical Oncology,2015,42(20):1018-1024.
[18]HAN B,KIM S,KOH J,et al.Immunophenotypic landscape and prognosis of diffuse large B-cell lymphoma with MYC/BCL2 double expression:An analysis of a prospectively immunoprofiled cohort [J].Cancers (Basel),2020,12(11):3305.
[19]WEBER T,SCHMITZ R.Molecular subgroups of diffuse large B cell lymphoma:Biology and implications for clinical practice[J].Curr Oncol Rep,2022,24(1):13-21.
[20]田荣华,应韶旭,李晓,等.PIM1表达与弥漫大B细胞淋巴瘤预后的关系[D].苏州:苏州大学,2010. TIAN RH,YING SX,LI X,et al.Prognostic signififi cance of PIM1 expression in primary nodal diffuse large B-cell lymphoma[D].Suzhou:Suzhou University,2010.


Last Update: 2023-05-31